Phosphorylated p38 MAP kinase expression by leucocytes is increased in allergic humans and associated with IgE responses.
IgE
MAP kinase
allergic rhinoconjunctivitis
allergy
asthma
mitogen‐activated protein kinase
phosphorylated ERK1/2
phosphorylated JNK
phosphorylated p38
Journal
Scandinavian journal of immunology
ISSN: 1365-3083
Titre abrégé: Scand J Immunol
Pays: England
ID NLM: 0323767
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
13
11
2023
received:
28
06
2023
accepted:
19
11
2023
medline:
5
3
2024
pubmed:
5
3
2024
entrez:
5
3
2024
Statut:
ppublish
Résumé
Mitogen-activated protein kinases (MAPK) activate cascades that regulate cell proliferation, differentiation and death. Phosphorylated (phos-)p38 MAPK is a cell-signalling pathway associated with Th2 cytokine responses, which is required for immunoglobulin (Ig)E production. It is unknown whether MAPK are associated with IgE production. We examine the evidence linking p38 MAPK to inflammatory responses. Phos-p38, extracellular signal-related kinase (ERK) and c-JUN-n terminal (JNK) MAPK expression by blood leucocyte subsets and levels of serum Igs were measured in blood from adults with asthma and/or rhinoconjunctivitis (N = 28) and non-asthma (N = 10) (flow cytometry, microfluorenzymeimmunoassay). Peripheral blood mononuclear cells (PBMC) from allergic subjects were cultured for 10 days ± anti-CD40/recombinant IL-4 ± inhibitor of phos-P38. Culture supernatants were assayed for IgE (ELISA). Phos-p38 MAPK expression by all leucocyte subsets of allergic subjects was associated with serum IgE levels (p ≤ 0.01), after adjusting for cell counts, age, sex, race and smoking status (p ≤ 0.04). Leucocyte expression of phos-ERK and JNK did not correlate with IgE (p = 0.09-0.99). Instead, phos-ERK expression was associated with serum IgG. When PBMC from atopic subjects were cultured for 10 days with anti-CD40/rhIL-4, IgE levels were 26.2 ± 18 ng/mL. Inclusion of SB202190 (5-20 μg/mL), a specific inhibitor of phos-p38 MAPK, in culture suppressed IgE production in dose-dependent manner, with peak suppression obtained with SB202190 at 20 μg/mL (82.1% ± 11.8) (p = 0.0001), with virtually no cytotoxicity (<5%). Different MAPK pathways may be associated with IgE (p38) and IgG (ERK) responses. Phos-p38 MAPK can be a potential anti-allergy drug target.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13343Subventions
Organisme : NY State Divisional Grant
Informations de copyright
© 2023 The Scandinavian Foundation for Immunology.
Références
Akinbami LJ, Moorman JE, Liu X. Asthma prevalence, health care use, and mortality: United States, 2005‐2009. Natl Health Stat Report. 2011;32:1‐14.
Gershon AS, Guan J, Wang C, To T. Trends in asthma prevalence and incidence in Ontario, Canada, 1996‐2005: a population study. Am J Epidemiol. 2010;172(6):728‐736.
Maneechotesuwan K, Xin Y, Ito K, et al. Regulation of Th2 cytokine genes by p38 MAPK‐mediated phosphorylation of GATA‐3. J Immunol. 2007;178(4):2491‐2498.
Macneil AJ, Yang YJ, Lin TJ. MAPK kinase 3 specifically regulates fc{varepsilon}RI‐mediated IL‐4 production by mast cells. J Immunol. 2011;187:3374‐3382.
Sancho‐Serra Mdel C, Simarro M, Castells M. Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcepsilonRI internalization. Eur J Immunol. 2011;41(4):1004‐1013.
Gowthaman U, Chen JS, Zhang B, et al. Identification of a T follicular helper cell subset that drives anaphylactic IgE. Science. 2019;365(6456):eaaw6433.
McKenzie GJ, Fallon PG, Emson CL, Grencis RK, McKenzie AN. Simultaneous disruption of interleukin (IL)‐4 and IL‐13 defines individual roles in T helper cell type 2‐mediated responses. J Exp Med. 1999;189(10):1565‐1572.
Expert Panel Report 3 (EPR‐3): guidelines for the diagnosis and management of asthma‐summary report 2007. J Allergy Clin Immunol. 2007;120(5 Suppl):S94‐S138.
Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA[2]LEN and AllerGen). Allergy. 2008;63(Suppl 86):8‐160.
Oppenheimer J, Nelson HS. Skin testing. Ann Allergy Asthma Immunol. 2006;96(2 Suppl 1):S6‐S12.
Smith‐Norowitz TA, Bluth MH, Drew H, et al. Effect of minocycline and doxycycline on IgE responses. Ann Allergy Asthma Immunol. 2002;89(2):172‐179.
Smith‐Norowitz TA, Silverberg J, Norowitz KB, et al. Two distinct T cell subsets, CD4+ and CD8+CD60+, and their cytokines are required for in vitro induction of human ragweed‐specific memory IgE responses. J Immunol. 2008;181(7):4761‐4769.
Graybill FA. An Introduction to Linear Statistical Models. McGraw‐Hill; 1961.
Pongratz G, McAlees JW, Conrad DH, Erbe RS, Haas KM, Sanders VM. The level of IgE produced by a B cell is regulated by norepinephrine in a p38 MAPK‐ and CD23‐dependent manner. J Immunol. 2006;177(5):2926‐2938.
Oh PS, Lim KT. IgE, COX‐2, and IL‐4 are expressed by DEHP through p38 MAPK and suppressed by plant glycoprotein (75 kDa) in ICR mice. Inflammation. 2010;34:326‐334.
Craxton A, Shu G, Graves JD, Saklatvala J, Krebs EG, Clark EA. P38 MAPK is required for CD40‐induced gene expression and proliferation in B lymphocytets. J Immunmol. 1998;161:3225‐3236.
Brady K, Fitzgerald S, Ingvarsson S, Borrebaeck CAK, Moynagh PN. CD40 employs p38 MAP kinase in IgE isotype switching. Biochem Biophys Res Commun. 2001;289:276‐281.
Arens R, Nolte MA, Tesselaar K, et al. Signaling through CD70 regulates B cell activation and IgG production. J Immunol. 2004;173(6):3901‐3908.
Li L‐b, Leung DYM, Goleva E. Activated p38 MAPK in peripheral blood monocytes of steroid resistant asthmatics. PloS One. 2015;10(10):e0141909.
Lee JH, Son SH, Kim NJ, Im DS. p38 MAPK inhibitor NJK14047 suppresses CDNB‐induced atopic dermatitis‐like symptoms in BALB/c mice. Biomol Ther (Seoul). 2022;30(6):501‐509.